Qianjiang Yongan Pharmaceutical002365.SZValuation Analysis

As of Oct 19, 2026, Qianjiang Yongan Pharmaceutical (002365.SZ) trades at a P/E of 66.00x, P/B of 1.77x, P/S of 3.13x, and a dividend yield of 0.82%.
Longitudinal percentile comparison: P/E sits at the 68th percentile over the trailing 10Y window (vs. 11th percentile over 3Y); P/B sits at the 47th percentile over the trailing 10Y window (vs. 55th percentile over 3Y); P/S sits at the 59th percentile over the trailing 10Y window (vs. 44th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 69th percentile within its industry and the 69th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.28%, ranking at the 67th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 20.4 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 1.28% total shareholder yield, 0.82% is paid out as dividends and roughly 0.46% is implied to come from buybacks — both channels are meaningfully in play. Qianjiang Yongan Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.